IMHO it is very reassuring to know that the Neuren management team have substantial experience in dealing with the FDA and the way it operates.The value of this experience is almost invaluable at this sharp end of the clinical trial process.
Kens
Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome, page-20
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.48 |
Change
-0.060(0.48%) |
Mkt cap ! $1.548B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.32 | $4.414M | 353.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 477 | $12.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 1225 | 10 |
View Market Depth
| Last trade - 14.21pm 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |